We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Join our healthcare community
Discover how Leqembi (lecanemab) targets and removes amyloid plaques to slow cognitive decline in early Alzheimer's disease. Learn about its mechanism, efficacy, potential side effects like ARIA, and who is eligible for this innovative treatment. A new hope for managing early-stage Alzheimer's.
Alzheimer's disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills, and eventually, the ability to carry out the simplest tasks. For decades, treatments have primarily focused on managing symptoms rather than altering the disease's underlying progression. However, the landscape of Alzheimer's treatment is evolving with the introduction of new disease-modifying therapies.
One such therapy is Leqembi (lecanemab), an intravenous medication that received accelerated approval from the U.S. Food and Drug Administration (FDA) in January 2023, and full approval in July 2023, for the treatment of early Alzheimer's disease. Leqembi represents a significant advancement because it targets one of the core pathological hallmarks of Alzheimer's: amyloid-beta plaques. This article delves into how Leqembi works, who it's for, its efficacy, potential side effects, and what patients and caregivers need to know.
To understand how Leqembi works, it's crucial to grasp the fundamental changes occurring in the brain of someone with Alzheimer's disease. The two primary pathological hallmarks are:
While both contribute to neuronal damage and death, amyloid plaques are believed to initiate the cascade of events leading to the disease. The amyloid cascade hypothesis suggests that the accumulation of amyloid-beta is an early and crucial event in Alzheimer's pathology.
Amyloid-beta is a protein fragment that is naturally produced in the brain. In a healthy brain, these fragments are cleared away. However, in Alzheimer's disease, for reasons not fully understood, these fragments misfold and aggregate, first into small, soluble clusters called protofibrils, then into larger, insoluble plaques. These accumulations disrupt cell function, communication between neurons, and eventually lead to cell death, contributing to the cognitive decline characteristic of Alzheimer's.
Leqembi, generically known as lecanemab, is a monoclonal antibody. Monoclonal antibodies are laboratory-produced molecules engineered to mimic the body's natural antibodies and target specific substances. In Leqembi's case, its target is the amyloid-beta protein.
Unlike some previous amyloid-targeting drugs that focused on mature, insoluble plaques, Leqembi specifically binds to and helps clear soluble amyloid-beta protofibrils. Protofibrils are small, aggregated forms of amyloid-beta that are believed to be particularly toxic to neurons and play a critical role in the formation and growth of amyloid plaques.
By targeting these protofibrils, Leqembi aims to:
The hypothesis behind Leqembi's action is that by reducing the amyloid burden in the brain, it can slow down the neurodegenerative process that leads to cognitive and functional decline in early Alzheimer's disease. It's important to understand that Leqembi is not a cure for Alzheimer's; rather, it is a disease-modifying therapy designed to slow the progression of the disease.
Leqembi is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment (MCI) due to Alzheimer's disease or mild dementia due to Alzheimer's disease. This means it is intended for individuals in the early stages of the disease, where amyloid pathology is present, but cognitive impairment is not yet severe.
Key eligibility criteria include:
Leqembi is administered as an intravenous (IV) infusion. This means the medication is delivered directly into a vein, typically in the arm, through a drip. The standard dosing regimen is an infusion every two weeks.
Patients receiving Leqembi require regular monitoring, including:
The full approval of Leqembi by the FDA was largely based on the results of the Phase 3 Clarity AD clinical trial, published in The New England Journal of Medicine.
While a 27% slowing of decline might seem modest, for a progressive disease like Alzheimer's, any intervention that can slow the deterioration of cognitive function and daily living activities is considered clinically meaningful. It offers patients more time with better cognitive function and independence.
Like all medications, Leqembi carries potential side effects. Patients and their caregivers must be aware of these risks, especially the more serious ones.
The most notable and serious side effects associated with Leqembi, and other amyloid-targeting therapies, are Amyloid-Related Imaging Abnormalities (ARIA). ARIA can manifest in two forms:
Risk Factors for ARIA:
Monitoring and Management of ARIA:
Less serious but more common side effects reported in clinical trials include:
It is essential for patients to report any new or worsening symptoms to their healthcare provider promptly.
Accurate and early diagnosis of Alzheimer's disease, along with confirmation of amyloid pathology, is paramount for patients to be considered for Leqembi treatment.
If you or a loved one are experiencing persistent memory problems or other changes in thinking, reasoning, or behavior, it is crucial to consult a healthcare professional. Early diagnosis is key to accessing treatments like Leqembi and to planning for the future.
Seek medical advice if you notice:
Discussing these symptoms with a doctor can lead to appropriate evaluation, diagnosis, and information about available treatment options, including disease-modifying therapies like Leqembi.
A: No, Leqembi is not a cure for Alzheimer's disease. It is a disease-modifying therapy that has been shown to slow the rate of cognitive and functional decline in patients with early Alzheimer's. It works by reducing amyloid plaques in the brain, which is believed to be a contributing factor to the disease's progression.
A: The duration of Leqembi treatment is ongoing, typically administered as an intravenous infusion every two weeks. The long-term effects and optimal duration of therapy are still being studied. Treatment continuation will depend on the patient's response, tolerance to the drug, and ongoing assessment by their healthcare provider.
A: ARIA stands for Amyloid-Related Imaging Abnormalities. It is a common side effect of amyloid-targeting therapies like Leqembi. ARIA can involve brain swelling (ARIA-E) or small brain bleeds (ARIA-H). While often asymptomatic, ARIA can sometimes cause symptoms like headache, confusion, dizziness, or vision changes. In rare cases, ARIA can be serious or life-threatening. Regular MRI monitoring is essential to detect and manage ARIA.
A: No, Leqembi is specifically indicated for patients with mild cognitive impairment (MCI) due to Alzheimer's or mild dementia due to Alzheimer's. Patients must also have confirmed amyloid-beta pathology in their brain. It is not approved for moderate or severe Alzheimer's disease, and its efficacy in these stages has not been established.
A: Previous Alzheimer's drugs (e.g., donepezil, rivastigmine, galantamine, memantine) primarily manage symptoms by improving neurotransmitter function. Leqembi, along with aducanumab (Aduhelm) and donanemab (another investigational drug), is a disease-modifying therapy that targets the underlying amyloid pathology of Alzheimer's. Leqembi specifically targets soluble amyloid-beta protofibrils, aiming to slow disease progression rather than just alleviate symptoms.
Leqembi (lecanemab) represents a significant milestone in the fight against Alzheimer's disease. By precisely targeting and clearing amyloid-beta protofibrils and plaques, it offers a new approach to slowing the progression of cognitive and functional decline in individuals with early Alzheimer's. While it is not a cure, it provides a valuable option for patients and their families, potentially extending the period of independence and quality of life.
The introduction of Leqembi underscores the importance of early diagnosis and ongoing research. As with any powerful medication, understanding its mechanism, eligibility criteria, and potential risks, particularly ARIA, is crucial. Patients and caregivers should engage in thorough discussions with their healthcare providers to determine if Leqembi is an appropriate treatment option, weighing its benefits against the potential risks in their individual circumstances. The journey toward fully conquering Alzheimer's continues, and Leqembi is a promising step on that path.
Visit Hospital
Near You
Confused about whether CBD can get you high? Understand the difference between CBD and THC, their effects on your body, and what to look for in safe, non-intoxicating CBD products.
April 1, 2026
Learn about anticoagulants and antiplatelet drugs, often called blood thinners. Understand how they prevent blood clots, when they're prescribed, their side effects, and essential safety tips for Indian readers.
April 1, 2026
Confused about Plan B and abortion pills? Understand the key differences, how they work, and their effectiveness for informed reproductive health decisions.
April 1, 2026